■先前的纵向队列研究报道了他汀类药物使用与肌腱病发展之间关系的矛盾结果。目前尚不清楚他汀类药物使用之间是否存在关系,特别是类型或累积剂量,和肌腱病的发展。
■探讨他汀类药物治疗与肌腱病发展之间的关系。
■队列研究;证据水平,3.
■2002年,共有594,130名参与者参加了这项研究,并进行了评估,直到2015年。使用倾向评分匹配分析,以1:2的比例选择了84,102名他汀类药物使用者和168,204名非使用者(对照)。包括肌腱病的类型如下:(1)触发手指,(2)桡骨茎突腱鞘炎,(3)肘关节上髁炎,(4)肩袖肌腱病,和(5)跟腱炎。构建了具有时变协变量的Cox比例风险模型,以确定他汀类药物使用与肌腱病发展之间的关联。
■无论他汀类药物类型如何,他汀类药物治疗都与所有类型的肌腱病发展的风险显着增加相关(风险比,1.435;95%CI,1.411-1.460)与没有他汀类药物治疗相比。根据累积他汀类药物剂量观察到风险降低的趋势,风险比为2.337(95%CI,2.269-2.406),2.210(95%CI,2.132-2.290),和1.1(95%CI,1.098-1.146),分别为90、91-180和>180的患者。
■这项全国性的基于人群的队列研究表明,与非使用者相比,无论他汀类药物类型如何,他汀类药物的使用与肌腱病的风险更大。肌腱病发展的风险随着累积确定的每日剂量的增加而被稀释。
UNASSIGNED: Previous longitudinal cohort studies have reported the conflicting results of the relationship between statin use and the development of tendinopathy disorder. It is unclear if there is a relationship between statin use, particularly the type or cumulative doses, and the development of tendinopathy disorder.
UNASSIGNED: To investigate an association between statin treatment and the development of tendinopathy.
UNASSIGNED: Cohort study; Level of evidence, 3.
UNASSIGNED: A total of 594,130 participants were enrolled in this study in 2002 and evaluated until 2015. There were 84,102 statin users and 168,204 nonusers (controls) selected at a ratio of 1:2 using propensity score matching analysis. The types of included tendinopathy were as follows: (1) trigger finger, (2) radial styloid tenosynovitis, (3) elbow epicondylitis, (4) rotator cuff tendinopathy, and (5) Achilles
tendinitis. Cox proportional hazards models with time-varying covariates were constructed to identify the association between statin use and tendinopathy development.
UNASSIGNED: Statin treatments regardless of statin types were associated with a significantly greater risk of all types of tendinopathy development (hazard ratio, 1.435; 95% CI, 1.411-1.460) compared with no statin treatment. A trend toward risk reduction was observed according to cumulative statin doses, which was indicated by hazard ratios of 2.337 (95% CI, 2.269-2.406), 2.210 (95% CI, 2.132-2.290), and 1.1 (95% CI, 1.098-1.146) in patients with cumulative defined daily doses of 90, 91-180, and >180, respectively.
UNASSIGNED: This nationwide population-based cohort study suggests that statin use regardless of the statin type was associated with a greater risk of tendinopathy compared with that of nonusers. The risk of tendinopathy development was diluted with the increasing cumulative defined daily dose.